 DUBLIN, Ireland, Nov. 04, 2020 GLOBE NEWSWIRE -- Prothena Corporation plc NASDAQ:PRTA, a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today reported financial results for the third quarter and first nine months of 2020. In addition, the Company provided an update on its RD programs. 